The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease

Table 2 Descriptive statistics for ADAS-cog, cognitive test battery, ADCS-ADL and CDR-SB (intent-to-treat cohort)

	Active product	Control product	P value^a
ADAS-cog
Baseline	23.89 ± 9.59 (258)	23.39 ± 9.34 (257)	0.550
Week 24	25.44 ± 11.56 (220)	24.42 ± 10.95 (208)	0.349
∆ week 24 – baseline	1.88 ± 6.44 (218)	1.52 ± 5.63 (207)	0.547 (0.513)
Cognitive Test Battery, z score
Baseline	0.08 ± 0.75 (228)	−0.02 ± 0.71 (235)	0.153
Week 24	0.09 ± 0.74 (182)	0.01 ± 0.71 (182)	0.260
∆ week 24 – baseline	−0.10 ± 0.47 (179)	−0.05 ± 0.40 (178)	0.301 (0.323)
ADCS-ADL total score
Baseline	57.95 ± 13.36 (265)	57.38 ± 13.37 (262)	0.623
Week 24	54.66 ± 15.56 (228)	54.15 ± 15.91 (223)	0.731
∆ week 24 – baseline	−3.74 ± 9.76 (228)	−3.66 ± 8.03 (223)	0.926 (0.767)
CDR-SB
Baseline	6.18 ± 3.01 (264)	6.45 ± 2.89 (259)	0.296
Week 24	6.89 ± 3.35 (227)	7.01 ± 3.41 (223)	0.709
∆ week 24 – baseline	0.77 ± 1.96 (226)	0.69 ± 1.90 (222)	0.676 (0.500)

Data presented as mean ± standard deviation (n). ADAS-cog, Alzheimer’s Disease Assessment Scale – Cognitive Subscale, ADCS-ADL, Alzheimer’s Disease Cooperative Study Activity of Daily Living; CDR-SB, Clinical Dementia Rating scale – Sum of Boxes; ∆, difference. ^aP values from t tests, active product versus control product, except for values in parentheses that are P values from mixed model for repeated measures.

ISSN: 1758-9193